Latest Attention-deficit hyperactivity disorder management Stories
A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors.
Adults with attention-deficit/hyperactive disorder (ADHD) are showing greater improvement when receiving individual sessions of cognitive behavioral therapy (CBT) in addition to their monthly medication.
Adults with attention-deficit/hyperactivity disorder (ADHD) who received medication and individual sessions of cognitive behavioral therapy (CBT) showed greater improvement in symptoms through 12 months compared to patients who did not receive CBT.
Adding cognitive behavioral therapy â€“ an approach that teaches skills for handling life challenges and revising negative thought patterns â€“ to pharmaceutical treatment for attention-deficit hyperactivity disorder (ADHD) significantly improved symptom control in a study of adult patients.
NEW YORK, Aug. 23 /PRNewswire/ -- A new ADD/ADHD study found that a multi-modal hemispheric based program significantly improved the participant's educational outcomes.
Rising rates of attention deficit hyperactivity disorder (ADHD) and large differences in diagnosis rates have led to fears that the condition is often being misdiagnosed.
DUBLIN, August 10, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the divestiture of Daytrana(R) (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc.
A new study from Perth's Telethon Institute for Child Health Research shows an association between ADHD and a 'Western-style' diet in adolescents.
MONMOUTH JUNCTION, N.J., July 28 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name MethylinÂ® Oral Solution marketed by Shionogi Pharmaceuticals, Inc. "Tris pursues selective generic opportunities, especially the difficult to formulate or complex formulations and...
DUBLIN and PHILADELPHIA, July 6 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of DaytranaÂ® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.
- A person in a secondary role, specifically the second most important character (after the protagonist).